The Scientific and Clinical Development team at Asceneuron is responsible for advancing therapeutic candidates from preclinical stages through early clinical trials. This includes developing translational medicine strategies, overseeing preclinical development, assessing ADME (absorption, distribution, metabolism, and excretion) and toxicology, and guiding non-clinical development and medicinal chemistry efforts. Their ultimate goal is to ensure the safety, efficacy, and regulatory approval of novel treatments for orphan tauopathies and Alzheimer’s disease.
View all